CHMP Recommends Approval of Maintenance Lenalidomide in Post-ASCT Myeloma

January 28th, 2017 – The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of lenalidomide as a maintenance therapy following autologous stem cell transplant (ASCT) for patients with newly diagnosed multiple myeloma, according to Celgene, the manufacturer of the treatment. The application is based on data from 2 phase III trials, CALGB 100104 and IFM 2005-02. Both studies were unblinded after post-ASCT maintenance … (leggi tutto)